CCLM

QIAGEN’s QuantiFERON-TB Gold Plus shows unique clinical value with CD8 technology in new meta-analysis of tuberculosis screening

Retrieved on: 
Thursday, June 15, 2023
Infection, TST, Systematic review, IGRA, CCLM, Tuberculosis, QIAGEN, QGEN, Medical laboratory, International, Comparison, Vaccination, Workflow, World Health Organization's response to the COVID-19 pandemic, Clinical Chemistry and Laboratory Medicine, Meta-analysis, CDC, BCG, Death, QuantiFERON, CD8, Padjadjaran University, Patient, Gold, Risk, Gamma ray, Diagnosis, CD4, TB2, Genetically modified bacteria, Immunodeficiency, Lymphocyte, WHO, NYSE, World Health Organization, Disease, Vaccine, Pharmaceutical industry, TB

The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).

Key Points: 
  • The study highlights QIAGEN’s continued leadership in TB infection screening, centered on QuantiFERON-TB Gold Plus test, an interferon-gamma release assay (IGRA).
  • The meta-analysis on QuantiFERON testing was conducted by Universitas Padjadjaran, Indonesia, and published in Clinical Chemistry and Laboratory Medicine (CCLM) [1] .
  • QuantiFERON-TB Gold Plus is the world’s leading IGRA blood test, with millions of tests performed annually.
  • [1] Darmawan, Guntur et al: "Comparison of interferon-gamma production between TB1 and TB2 tubes of QuantiFERON-TB Gold Plus: a meta-analysis" Clinical Chemistry and Laboratory Medicine (CCLM), 2023. https://doi.org/10.1515/cclm-2023-0293

Global Liver Metastases Treatment Market Report 2023: Sector is Expected to Reach $2.31 Billion by 2030 at a CAGR of 7.2% - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 14, 2023
Health, Pharmaceutical, CCLM, Prevalence, Liver disease, Hospital, Cancer, Lung cancer, Large intestine, Colorectal cancer, Incidence, Developed country, Liver, Diagnosis, Breast cancer, Pharmaceutical industry, Medical imaging

The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030.

Key Points: 
  • The incidence of colorectal cancer is expected to increase from 1.88 million in 2020 to 2.45 million in 2030.
  • Whereas the incidence of breast cancer is expected to increase from 2.26 million in 2020 to 2.74 million in 2030.
  • In 2022, colorectal cancer dominated the liver metastases treatment market with a share of 40.55%.
  • By region, North America has a high revenue share in global liver metastases treatment market in 2022.

Agiloft And Ready Computing Announce Partnership To Bring Enhanced CLM To The Healthcare Marketplace

Retrieved on: 
Tuesday, February 15, 2022
Ecosystem, Health information exchange, Contract, VP, CLM, Solution, Efficiency, Technology, Partnership, Automation, CCLM, System, Industry, Construction, Risk management, Agiloft

REDWOOD CITY, Calif., Feb. 15, 2022 /PRNewswire/ -- Agiloft , the global standard in no-code contract lifecycle management (CLM), today announced a strategic partnership with Ready Computing to enhance the use of the Agiloft platform in the healthcare marketplace.

Key Points: 
  • REDWOOD CITY, Calif., Feb. 15, 2022 /PRNewswire/ -- Agiloft , the global standard in no-code contract lifecycle management (CLM), today announced a strategic partnership with Ready Computing to enhance the use of the Agiloft platform in the healthcare marketplace.
  • A leader in healthcare IT services and solutions, Ready Computing is recognized for its in-depth expertise in healthcare interoperability and large-scale connected care solutions.
  • With its extensive system integrator (SI) knowledge and understanding of the challenges facing healthcare organizations, Ready Computing is an ideal service partner for the introduction of Agiloft as an integrative business solution.
  • "We are very excited to partner with Ready Computing to both expand possibilities and increase productivity in the healthcare enterprise,"said Elisabeth Bykoff, VP of Global Alliances at Agiloft.

Agiloft Summit 2019 Unites Customers, Partners for Future of Contract and Commerce Lifecycle Management in Las Vegas

Retrieved on: 
Tuesday, October 22, 2019
Product management, Lifecycle management, Microsoft Office, Innovation, CCLM, Articles, Business, Science

REDWOOD CITY, Calif., Oct. 22, 2019 /PRNewswire/ -- Agiloft , the global standard in contract and commerce lifecycle management, is hosting its first-ever user conference October 22-23 at the Mandalay Bay in Las Vegas.

Key Points: 
  • REDWOOD CITY, Calif., Oct. 22, 2019 /PRNewswire/ -- Agiloft , the global standard in contract and commerce lifecycle management, is hosting its first-ever user conference October 22-23 at the Mandalay Bay in Las Vegas.
  • Agiloft Summit 2019 brings together customers, partners, and staff to discuss emerging industry trends and how customers innovate with Agiloft to overcome challenges, boost productivity, and reduce risk.
  • At the Summit, Agiloft will also introduce the future of contract and commerce lifecycle management (CCLM) with Pierre Mitchell, managing director and chief research officer for Spend Matters .
  • CCLM is an emerging contract-centric methodology that extends well beyond traditional contract lifecycle management.